LUND, Sweden, March 12, 2018 /PRNewswire/ --
The Board of Directors of Immunovia AB (publ) ("Immunovia" or
the "Company") has today adopted financial targets due to the fact
the Company, as previously announced, will begin sales during
second half of 2018. The financial targets show that the Company's
goal is to reach SEK 250-300 million
in turnover in 2021 based on "self-pay"-sales and a turnover of
SEK 800-1,000 million in 2023
including self-pay and reimbursements in Europe and the US.
Immunovia performs clinical validation studies for the
commercialization of IMMray™ PanCan-d, which may be the first
blood-based test for early diagnosis of pancreatic cancer. Market
introductory preparations have begun in 2017 and the commercial
organization is constantly being strengthened in 2018 in order to
implement market launch activities. The Company expects the first
revenues from self-pay sales during the fourth quarter of 2018.
The following financial targets have been adopted:
- Immunovia's targets to achieve a turnover of SEK 250-300 million in 2021 based on self-pay for
IMMray™ PanCan-d.
- Immunovia targets further to achieve a total turnover,
for self-pay and reimbursement, of SEK
800-1,000 million in 2023.
The target of SEK 250-300 million
in turnover in 2021, which is three years after sales start in
Europe and the United States, is based on self-pay, i.e.
that users themselves pay for the product. This corresponds to
approximately five percent market penetration in the category of
familiar or hereditary risk of pancreatic cancer and one percent
market penetration in the category early symptoms of pancreatic
cancer.
Immunovia targets to receive reimbursement for IMMray™ PanCan-d
in these segment of pancreatic cancer in 2021. Immunovia's goal of
reaching SEK 800-1,000 million in
total sales for self-pay and reimbursement in 2023 in Europe and the
United States corresponds to approximately twenty percent
market penetration in the category of hereditary risk of pancreatic
cancer, nine percent penetration in the category early symptoms of
pancreatic cancer, and an initial use in the area of diabetic
patients with increased risk of pancreatic cancer.
The financial targets apply to IMMray™ PanCan-d, the first of
several uses with significant market potential for the IMMray™
platform, such as autoimmune diseases and other cancers. The
company initiated a program focusing on diagnostics and monitoring
of autoimmune diseases in the beginning of 2016.
Immunovia's financial targets set forth above constitute
forward-looking information and are based on a number of
assumptions about the environment in which the Company operates,
which may vary significantly and deteriorate over time from what
Immunovia assessed when the financial targets were adopted. As a
consequence, Immunovia's ability to achieve the financial targets
consists of uncertainties and contingencies, some of which are
outside the Company's control. There is no guarantee that Immunovia
can achieve the financial targets or that Immunovia's financial
position or operating profit will not differ materially from the
financial targets.
For more information, please contact:
Mats Grahn
Chief Executive Officer, CEO, Immunovia
Tel.: +46-70-5320230
Email: mats.grahn@immunovia.com
This information is information that Immunovia AB (publ) is
obliged to make public pursuant to the EU Market Abuse Regulation.
The information was submitted for publication on 12 March at CET
08:30, through the agency of the contact person set out
above.
This information was brought to you by Cision
http://news.cision.com
http://news.cision.com/immunovia-ab/r/immunovia-announces-financial-targets,c2469845
The following files are available for download:
http://mb.cision.com/Main/13121/2469845/803907.pdf
|
Press release
financial targets
|